Laurent Azoulay

Full Professor @McGillU; Pharmacoepidemiologist

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

Initiation of #GLP-1 receptor agonists, most notably semaglutide, is associated with an increased one-year risk of NAION compared with DPP-4 inhibitors in adults with #T2D.
@PROFLAZOULAY

Read here ➡️ https://t.co/rheyO1TVfZ

@AmDiabetesAssn @ADA_DiabetesPro @ADA_Pubs

[Healio @GoHealio]

🩺 A recent study added to the growing body of evidence indicating #GLP1 receptor agonists do not affect suicidality. #HealthNews
Read more, with insight from @profLAzoulay, one of the researchers, and @dameofdementia, of @AOAforDOs ⬇️
https://t.co/68NCSwsm6J

[The BMJ @bmj_latest]

Use of GLP-1 receptor agonists to treat type 2 diabetes is not associated with an increased risk of suicidality compared with two other groups of diabetes drugs known as DPP-4 inhibitors and SGLT-2 inhibitors, finds study of UK health data @profLAzoulay https://t.co/splZrR1Qpq

[Samantha B. Shapiro, MSc @SShapiro_97]

Very proud of this study in @bmj_latest showing no association between GLP-1 RAs and suicidality. Thankful to be working with such a great team!

[Laurent Azoulay @profLAzoulay]

Concerns have been raised about a possible link between GLP-1 RAs and suicidality. Our latest study published in the @bmj_latest provides reassuring findings.

Great work by my doctoral student Samantha Shapiro and team!

https://t.co/tP4kFtqoja

[Laurent Azoulay @profLAzoulay]

I am pleased to share our latest study published in Diabetes Care!

Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors and the Prevention of Cirrhosis Among Patients With Type 2 Diabetes https://t.co/9QGLpDgg4C

[Giada Sebastiani @GiadaSebastiani]

🚨Pleased to coauthor this new publication🚨
➡️In patients with type 2 #diabetes in UK, SGLT-2 inhibitors were associated with a lower risk of #cirrhosis compared to DPP-4 inhibitors
➡️ #GLP1 RAs were not associated with a lower risk of cirrhosis
👉https://t.co/9wt8t8uhRK

[Samantha B. Shapiro, MSc @SShapiro_97]

🚨Fresh off the press in @DrugSafetyJ!

We observed a 46% increased risk of gallbladder and bile duct disease associated with use of DPP-4 inhibitors. Give it a read at https://t.co/KcyLolgS9g

@profLAzoulay #rxepi 💊

[Laurent Azoulay @profLAzoulay]

Additional studies, including randomized controlled trials, will be needed to fully explore the therapeutic potential of this combination.

Special thanks to our collaborators on this study!

@LDI_ILD @mcgillu @McGill_SPGH #McGillRxEpi

[Laurent Azoulay @profLAzoulay]

I am pleased to share our latest study in the @bmj_latest

Using GLP-1 RAs and SGLT-2 inhibitors in combination was associated with a 30% decreased risk of MACE, compared with either drug class alone. Similar benefits were observed for renal outcomes.

https://t.co/UkW0Pq6gtd

[Samantha B. Shapiro, MSc @SShapiro_97]

Excited to share my first paper with @profLAzoulay on the association between SGLT-2 inhibitor use and the risk of lung cancer. Check out my first official foray into cancer pharmacoepidemiology in @BritJClinPharm! 💊🧫 #rxepi
https://t.co/Be3NFLgcwK

[Anita Koushik @AnitaKoushik]

#Postdoc fellowship opportunity in Cancer Pharmacoepidemiology, working with me and @LaurentAzoulay0

[Laurent Azoulay @profLAzoulay]

@SShapiro_97 @IntPharmacoEpi @robertwplatt Beautifully delivered presentation, well done!

[Laurent Azoulay @profLAzoulay]

@AlviRahman_ @GreenJournal Well done, congrats!

[Laurent Azoulay @profLAzoulay]

Do PPIs increase the risk of IBD?

In this study published in @GUTJournal_BMJ, we show how short-term use is spuriously associated with IBD, likely due to protopathic bias. Lagging the exposures generated null results.

https://t.co/JtBmhHClhW

@RussellYanofsky @DrEmilyMcD

[JAHA @JAHA_AHA]

No increased risk of #pancreatic #cancer in large cohort study of >350K new users of dihydropyridine calcium channel blockers @julie_rouette @LaurentAzoulay0 @DrEmilyMcD @brophyj @SchusterTibor #AHAJournals https://t.co/nwlsix0OBj

[The BMJ @bmj_latest]

GLP-1 receptor agonists and SGLT-2 inhibitors were associated with a reduced risk of severe exacerbations compared with sulfonylureas in patients with COPD and type 2 diabetes, finds study @LaurentAzoulay0

Includes a #VisualAbstract #BMJInfographic
https://t.co/pQ3GCIWGgX

[Laurent Azoulay @profLAzoulay]

I am pleased to share our latest paper published in @bmj_latest. In this study, GLP-1 RAs and SGLT-2Is were associated with a reduced risk of COPD exacerbations. Is there a role for these drugs in COPD? Great effort led by Richeek Pradhan.
@McGill_SPGH @LDI_ILD #McGillRxEpi

[Diabetes Care, an ADA research journal 🌟 @DiabetesCareADA]

International, multi-site, cohort study of adults w/ #T2DM suggests that use of SGLT2 inhibitors is not associated with increased risk of short-term bladder cancer. Findings should provide reassurance to patients and physicians #RWE @mcgillu @Harvard

👀➡️https://t.co/UL8haSOyDg

[Samantha B. Shapiro, MSc @SShapiro_97]

Patients with #type2diabetes using #SGLT2 inhibitors did not have a decreased risk of #lungcancer when compared to #DPP4 inhibitor users. For more details, check out poster 86 at #ICPE22 or read our preprint on #medRxiv: https://t.co/LDsbOz32CM